Source: Annual Congress 2010 - Best supportive care and palliation for lung cancer patients



Rating:

Share or cite this content

Citations should be made in the following way:
S. Alpar, B. Kurt, U. Turay, M. Gülhan, B. Ulubas, C. Özdilekcan, H. Bayiz, N. Basay, S. Aslan, M. Önal, S. Arinç, S. S. Hacievliyagil, E. Akpinar, D. Ernam, M. Kiyik (Ankara, Bolu, , Sivas, Istanbul, Malatya, Turkey). The reasons and frequency of complementary and alternative medication (CAM) use among lung cancer patients. Eur Respir J 2010; 36: Suppl. 54, 3301

Member's Comments

No comment yet.

Related content which might interest you: The treatment of tobacco dependence: an effective treatment for lung cancer Source: Annual Congress 2012 - Treatment of tobacco dependence as a treatment of lung diseases Year: 2012 Real-world treatment patterns and outcomes of patients with extensive disease small cell lung cancer (ED SCLC) Source: International Congress 2019 – Treatment of lung cancer Year: 2019 Use of alternative therapies in patients with asthma and COPD: is there any difference? Source: Eur Respir J 2005; 26: Suppl. 49, 504s Year: 2005 Which patients with COPD can potentially benefit from prophylactic use of antibiotics? Source: Annual Congress 2007 - Different aspects of COPD exacerbations Year: 2007 The use of Prevexair application in patients with COPD. Source: International Congress 2019 – Clinical implications of COPD management Year: 2019 Precision medicine for lung cancer: new targeted treatments  Source: International Congress 2017 – Precision medicine approaches in lung cancer Year: 2017 First hospitalization in lung cancer patients – is timing important? Source: Virtual Congress 2021 – Screening, diagnosis, management and prognosis of lung cancer Year: 2021 Do different combinations of bronchodilator therapies have different effects on health status in patients with COPD? Source: Eur Respir J 2003; 22: Suppl. 45, 52s Year: 2003 Single inhaler triple therapy in patients with advanced COPD: healthcare resource utilisation and cost data from the FULFIL study Source: International Congress 2017 – Does economisation of medicine transfer into benefits for patients? Year: 2017 COPD and new treatment options: the role of primary care Source: International Congress 2014 – Primary Care Programme "Management of COPD and other respiratory conditions in clinical practice" Year: 2014 General practitioner (GP) communication with potential lung cancer patients; review of practices prior to onward secondary care referral Source: Annual Congress 2011 - Quality management for lung cancer patients Year: 2011 Comparing the use and timing of palliative care services in COPD and lung cancer: a population-based survey Source: Eur Respir J, 51 (5) 1702405; 10.1183/13993003.02405-2017 Year: 2018 Using remote directly observed therapy (R-DOT) for optimising asthma therapy. Source: International Congress 2017 – Small airways, long distances and large databases in paediatric asthma Year: 2017 Fluticasone/salmeterol combination (FSC) is safe and provides effective long-term (52 week) control in the management of patients with persistent asthma (PA) Source: Eur Respir J 2001; 18: Suppl. 33, 176s Year: 2001 Validation of a gene-based lung cancer risk test (Respiragene) for high risk smokers: A targeted approach to early detection of lung cancer Source: Annual Congress 2010 - Lung cancer, idiopathic pulmonary fibrosis and sarcoidosis: the genetic approach Year: 2010 Non small cell lung cancer: options and outcome of treatment beyond second line Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology Year: 2020 Systematic evaluation of the efficacy-effectiveness gap of systemic treatments in extensive disease small cell lung cancer (ED SCLC) Source: International Congress 2019 – Treatment of lung cancer Year: 2019 Identifying subgroups of asthma patients for potential intervention using electronic medication monitors (EMM) Source: Virtual Congress 2020 – Personalised treatment of obstructive diseases Year: 2020 Analysis of clinical factors in relationship to treatment effects of erlotinib in non small cell lung cancer (NSCLC) patients Source: Annual Congress 2008 - Therapy of thoracic tumours Year: 2008